Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | AML: what to look forward to at ASH 2020

Thomas Prebet • 18 Nov 2020
ASH 2020
Acute Myeloid Leukemia Leukemia

Thomas Prebet, MD, PhD, Yale School of Medicine, New Haven, CT, outlines what he’s looking forward to at this year’s virtual ASH conference. This includes greater insight into the management of molecularly-defined disease and new agents that are rising as potentially active treatments for acute myeloid leukemia (AML). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Thomas Prebet, MD, PhD, has done consultancy work for BMS and AbbVie and has received research support from BMS and Jazz.

More from Thomas Prebet

3:31
Risk stratified analysis of CPX-351 versus 7 + 3 in older adults with AML
Thomas Prebet • 18 Nov 2020
1:50
Hypomethylating agent based combinations in MDS
Thomas Prebet • 18 Nov 2020
1:19
New treatments for AML
Thomas Prebet • 7 Oct 2020
1:51
Treating AML patients who are not eligible for intensive chemotherapy
Thomas Prebet • 7 Oct 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals